Employees: 1,181
Size Zhong Zhu Healthcare (600568.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $562M, the 3413th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥1.92 on 18 Nov 2026.
Performance Over six months the shares fell 21.9%, against -22.7% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 5.5% over the last twelve months (peer median +4.6%); the operating margin is -33.8% (peer median 6.3%).
Valuation It trades at 6.2× enterprise value to sales against a peer median of 3.7× (8th most expensive of 18).
Capital Return on invested capital runs 14.1 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥536M | CN¥576M | CN¥520M | CN¥636M | CN¥504M |
| Revenue growth | — | +11% | -18% | +26% | — |
| Gross profit | CN¥85.4M | CN¥74.3M | CN¥36.0M | CN¥107M | CN¥66.7M |
| EBITDA | n/a | -CN¥66.4M | -CN¥208M | -CN¥45.1M | -CN¥139M |
| Net income | -CN¥153M | -CN¥114M | -CN¥620M | -CN¥344M | -CN¥799M |
| Free cash flow | -CN¥4.50M | CN¥32.4M | CN¥24.9M | -CN¥23.7M | CN¥913,940 |
| Capital expenditure | CN¥20.6M | CN¥32.1M | CN¥12.8M | CN¥27.3M | CN¥26.0M |
| Total debt | CN¥44.5M | CN¥23.5M | CN¥16.4M | CN¥23.9M | CN¥275M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600568.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.7% | -11.4% | 9th highest of 21 |
| 6-month return | -21.9% | -22.7% | 10th highest of 20 |
| Distance from 52-week high | -41.3% | -43.4% | 9th highest of 21 |
| Revenue growth (TTM) | -5.5% | +4.6% | 7th lowest of 19 |
| Operating margin | -33.8% | 6.3% | 6th lowest of 18 |
| EV / Sales | 6.2× | 3.7× | 8th most expensive of 18 |
| ROIC minus cost of capital | -14.1 pp | -3.6 pp | 4th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |